These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25131591)

  • 21. Spreading of α-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis.
    Lamberts JT; Hildebrandt EN; Brundin P
    Neurobiol Dis; 2015 May; 77():276-83. PubMed ID: 25046996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.
    Hansen C; Björklund T; Petit GH; Lundblad M; Murmu RP; Brundin P; Li JY
    Neurobiol Dis; 2013 Aug; 56():145-55. PubMed ID: 23643841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein.
    Wersinger C; Jeannotte A; Sidhu A
    Eur J Neurosci; 2006 Dec; 24(11):3141-52. PubMed ID: 17156375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP.
    Kim S; Cho SH; Kim KY; Shin KY; Kim HS; Park CH; Chang KA; Lee SH; Cho D; Suh YH
    J Neurochem; 2009 Jun; 109(5):1483-96. PubMed ID: 19457162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Contribution of
    Longhena F; Faustini G; Missale C; Pizzi M; Spano P; Bellucci A
    Neural Plast; 2017; 2017():5012129. PubMed ID: 28133550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
    Sidhu A; Wersinger C; Vernier P
    FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease.
    Calì T; Ottolini D; Brini M
    Biofactors; 2011; 37(3):228-40. PubMed ID: 21674642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redox activity of α-synuclein-Cu is silenced by Zn₇-metallothionein-3.
    Meloni G; Vašák M
    Free Radic Biol Med; 2011 Jun; 50(11):1471-9. PubMed ID: 21320589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
    Bobela W; Aebischer P; Schneider BL
    Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
    Eschbach J; Danzer KM
    Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
    Park JY; Paik SR; Jou I; Park SM
    Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.